SUPPLEMENTAL INFORMATION Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial

Published: 01-07-2021| Version 1 | DOI: 10.17632/xjn2xnpk2h.1
Contributor:
Ricardo Rojo

Description

Supplemental material for Manuscript: Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial (JAAD-D-21-00517R1)

Files